The Drug-Delivery Company That Partnerships Built

By Cindy Dubin, Contributing Writer

Partnerships have been important to Arcturus Therapeutics, especially during the early phases of growth. Prior to becoming a public company in 2017, Arcturus was funded primarily (80 perecent) by strategic partners. “Non-dilutive monies, during the early stages of a company, provide essential funding and validate the science,” says Joseph Payne, president and CEO of Arcturus, a preclinical RNA medicines company. “Normally a company raises money, does its science, and hopes to get a deal. We were the inverse of that, getting money early from strategic partnerships and then transitioning to becoming a public company.”